SARASOTA, Fla., July 22, 2026
Lakewood-Amedex Biotherapeutics Inc. has announced new preclinical resistance data supporting its lead antimicrobial candidate Nu-3, reinforcing its potential role in addressing the growing global challenge of antibiotic-resistant bacteria. The company released the findings in response to the priorities outlined by the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB), which recently convened to help shape the next five-year U.S. National Action Plan on Combating Antibiotic-Resistant Bacteria (AMR). The data demonstrate that Nu-3, a Phase 2-ready therapeutic candidate for the treatment of infected diabetic foot ulcers (iDFU), possesses a high barrier to bacterial resistance through its proprietary Bisphosphocin® platform. By physically disrupting bacterial membranes rather than targeting conventional biochemical pathways, the investigational therapy has shown broad-spectrum antimicrobial activity against multiple drug-resistant pathogens, highlighting its promise as a next-generation treatment for serious infectious diseases.
Nu-3 Demonstrates Strong Barrier to Antimicrobial Resistance
The latest laboratory findings strengthen the scientific profile of Nu-3, which has previously demonstrated that it does not induce bacterial resistance during serial passage experiments—a key challenge facing many conventional antibiotics. Unlike traditional antimicrobial agents that target specific bacterial enzymes or proteins, Nu-3 utilizes a unique physical mechanism of action, disrupting bacterial cell membranes directly. This innovative approach significantly reduces the likelihood of bacteria developing resistance while maintaining potent antimicrobial activity. Laboratory studies further showed that the investigational therapy remained effective against bacteria carrying a wide range of resistance mechanisms, including target mutation resistance, antibiotic metabolism, and efflux pump-mediated resistance. These characteristics position Nu-3 as a highly differentiated antimicrobial candidate capable of addressing one of the most urgent global public health threats.
Broad-Spectrum Activity Supports Infectious Disease Innovation
According to Lakewood-Amedex, Nu-3 demonstrated broad-spectrum in vitro activity against multiple clinically significant bacterial pathogens that exhibit resistance to existing antibiotics. The candidate remained active against organisms carrying vanA and vanB variants, mec gene mutations, β-lactamase enzymes including NDM, ESBL, AmpC, and CRE, as well as bacteria utilizing efflux pump mechanisms that commonly reduce antibiotic effectiveness. This broad resistance profile suggests that Nu-3 could provide an important therapeutic option for difficult-to-treat infections, particularly infected diabetic foot ulcers, where multidrug-resistant bacteria frequently complicate treatment. The company believes its Bisphosphocin® antimicrobial platform represents a new generation of anti-infective therapies capable of overcoming resistance mechanisms that continue to undermine conventional antibiotics worldwide.
Advertisement
Clinical Development Aligns with National AMR Priorities
The announcement closely aligns with the priorities established by PACCARB and the evolving U.S. National Action Plan on Combating Antibiotic-Resistant Bacteria, both of which emphasize accelerating the development of innovative antimicrobial therapies capable of overcoming resistance. As a clinical-stage biotechnology company, Lakewood-Amedex Biotherapeutics is advancing Nu-3 toward Phase 2 clinical development, focusing initially on patients suffering from infected diabetic foot ulcers, a condition associated with significant morbidity, hospitalizations, and rising healthcare costs. By bypassing conventional bacterial resistance pathways through its membrane-disrupting mechanism, Nu-3 has the potential to expand treatment options for patients with serious bacterial infections while supporting national and global efforts to combat antimicrobial resistance (AMR). The newly released resistance data further strengthen the company’s position as a developer of innovative anti-infective therapeutics designed to address one of modern medicine’s most pressing challenges.
Source: Lakewood-Amedex Biotherapeutics Press release
